COVID-19 幸存者合并医院获得性急性肾损伤的长期预后:与急性肾损伤恢复时间的关系。
Long-term outcomes of COVID-19 survivors with hospital AKI: association with time to recovery from AKI.
机构信息
Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
Center for Health Data Innovation, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
出版信息
Nephrol Dial Transplant. 2023 Sep 29;38(10):2160-2169. doi: 10.1093/ndt/gfad020.
BACKGROUND
Although coronavirus disease 2019 (COVID-19) patients who develop in-hospital acute kidney injury (AKI) have worse short-term outcomes, their long-term outcomes have not been fully characterized. We investigated 90-day and 1-year outcomes after hospital AKI grouped by time to recovery from AKI.
METHODS
This study consisted of 3296 COVID-19 patients with hospital AKI stratified by early recovery (<48 hours), delayed recovery (2-7 days) and prolonged recovery (>7-90 days). Demographics, comorbidities and laboratory values were obtained at admission and up to the 1-year follow-up. The incidence of major adverse cardiovascular events (MACE) and major adverse kidney events (MAKE), rehospitalization, recurrent AKI and new-onset chronic kidney disease (CKD) were obtained 90-days after COVID-19 discharge.
RESULTS
The incidence of hospital AKI was 28.6%. Of the COVID-19 patients with AKI, 58.0% experienced early recovery, 14.8% delayed recovery and 27.1% prolonged recovery. Patients with a longer AKI recovery time had a higher prevalence of CKD (P < .05) and were more likely to need invasive mechanical ventilation (P < .001) and to die (P < .001). Many COVID-19 patients developed MAKE, recurrent AKI and new-onset CKD within 90 days, and these incidences were higher in the prolonged recovery group (P < .05). The incidence of MACE peaked 20-40 days postdischarge, whereas MAKE peaked 80-90 days postdischarge. Logistic regression models predicted 90-day MACE and MAKE with 82.4 ± 1.6% and 79.6 ± 2.3% accuracy, respectively.
CONCLUSION
COVID-19 survivors who developed hospital AKI are at high risk for adverse cardiovascular and kidney outcomes, especially those with longer AKI recovery times and those with a history of CKD. These patients may require long-term follow-up for cardiac and kidney complications.
背景
虽然患有院内急性肾损伤(AKI)的 2019 年冠状病毒病(COVID-19)患者短期预后较差,但他们的长期预后尚未得到充分描述。我们通过 AKI 恢复时间将住院 AKI 分组,研究了 COVID-19 患者在院内 AKI 后的 90 天和 1 年的结局。
方法
这项研究包括 3296 名 COVID-19 合并医院 AKI 的患者,根据早期恢复(<48 小时)、延迟恢复(2-7 天)和延长恢复(>7-90 天)进行分层。在入院时和 1 年随访时获得人口统计学、合并症和实验室值。在 COVID-19 出院后 90 天获得主要不良心血管事件(MACE)和主要不良肾脏事件(MAKE)、再住院、复发性 AKI 和新发慢性肾脏病(CKD)的发生率。
结果
院内 AKI 的发生率为 28.6%。在合并 AKI 的 COVID-19 患者中,58.0%为早期恢复,14.8%为延迟恢复,27.1%为延长恢复。AKI 恢复时间较长的患者 CKD 患病率较高(P<0.05),更有可能需要有创机械通气(P<0.001)和死亡(P<0.001)。许多 COVID-19 患者在 90 天内发生 MAKE、复发性 AKI 和新发 CKD,延长恢复组的发生率更高(P<0.05)。MACE 的发生率在出院后 20-40 天达到峰值,而 MAKE 的发生率在出院后 80-90 天达到峰值。Logistic 回归模型预测 90 天 MACE 和 MAKE 的准确率分别为 82.4±1.6%和 79.6±2.3%。
结论
患有院内 AKI 的 COVID-19 幸存者发生不良心血管和肾脏结局的风险很高,尤其是那些 AKI 恢复时间较长和有 CKD 病史的患者。这些患者可能需要长期随访心脏和肾脏并发症。